1. Home
  2. FISI vs ABUS Comparison

FISI vs ABUS Comparison

Compare FISI & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Financial Institutions Inc.

FISI

Financial Institutions Inc.

SELL

Current Price

$40.44

Market Cap

757.7M

Sector

Finance

ML Signal

SELL

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

SELL

Current Price

$4.06

Market Cap

836.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FISI
ABUS
Founded
1817
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
836.0M
IPO Year
1999
2008

Fundamental Metrics

Financial Performance
Metric
FISI
ABUS
Price
$40.44
$4.06
Analyst Decision
Hold
Analyst Count
2
0
Target Price
★ $45.00
N/A
AVG Volume (30 Days)
92.0K
★ 2.7M
Earning Date
10-29-2026
11-16-2026
Dividend Yield
★ 3.25%
N/A
EPS Growth
★ 231.27
55.26
EPS
★ 2.08
0.84
Revenue
N/A
★ $14,083,000.00
Revenue This Year
$6.23
$1,208.75
Revenue Next Year
$4.91
N/A
P/E Ratio
$18.88
★ $4.61
Revenue Growth
N/A
★ 128.21
52 Week Low
$28.21
$3.50
52 Week High
$42.97
$5.45

Technical Indicators

Market Signals
Indicator
FISI
ABUS
Relative Strength Index (RSI) 44.75 29.13
Support Level $37.87 $3.50
Resistance Level $40.33 $4.57
Average True Range (ATR) 0.83 0.15
MACD 0.01 -0.00
Stochastic Oscillator 34.27 1.96

Price Performance

Historical Comparison
FISI
ABUS

About FISI Financial Institutions Inc.

Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: